_256_384.jpg)
Drug Approval | April 14, 2024
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
A game changing solution for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
New leadership team announced at NATHEALTH Annual General Meeting 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The facility will manufacture tablets, capsules, and injections for the oncology segment
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Subscribe To Our Newsletter & Stay Updated
